GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (NAS:SESN) » Definitions » EV-to-Revenue

Sesen Bio (Sesen Bio) EV-to-Revenue : -1.19 (As of May. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sesen Bio EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sesen Bio's enterprise value is $-47.65 Mil. Sesen Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 was $40.00 Mil. Therefore, Sesen Bio's EV-to-Revenue for today is -1.19.

The historical rank and industry rank for Sesen Bio's EV-to-Revenue or its related term are showing as below:

SESN's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.98
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-04), Sesen Bio's stock price is $0.6288. Sesen Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $3.98. Therefore, Sesen Bio's PS Ratio for today is 0.16.


Sesen Bio EV-to-Revenue Historical Data

The historical data trend for Sesen Bio's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio EV-to-Revenue Chart

Sesen Bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 12.21 - -1.08

Sesen Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.23 1.01 -1.52 -1.08

Competitive Comparison of Sesen Bio's EV-to-Revenue

For the Biotechnology subindustry, Sesen Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sesen Bio's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sesen Bio's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sesen Bio's EV-to-Revenue falls into.



Sesen Bio EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sesen Bio's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-47.652/40
=-1.19

Sesen Bio's current Enterprise Value is $-47.65 Mil.
Sesen Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sesen Bio  (NAS:SESN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sesen Bio's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.6288/3.981
=0.16

Sesen Bio's share price for today is $0.6288.
Sesen Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.98.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sesen Bio EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sesen Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sesen Bio (Sesen Bio) Business Description

Traded in Other Exchanges
N/A
Address
245 First Street, Suite 1800, Cambridge, MA, USA, 02142
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.
Executives
Modernatx, Inc. 10 percent owner 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly director, officer: President and CEO C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris officer: Chief Financial Officer 397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206
Bjorn Odlander director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Michael Klichinsky officer: Chief Scientific Officer C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Elly Ryu officer: Principal Accounting Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Glen C Macdonald officer: Chief Technology Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Monica Forbes officer: Chief Financial Officer 3344 NORTH TORREY PINES CT., SUITE 200, SAN DIEGO CA 92037
Thomas R Cannell director, officer: President and CEO C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Mark Sullivan officer: General Counsel & Secretary 1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054